rs58194899 — EIPR1

EIPR1 — The Vesicle Trafficker That Sets Your Pain Thermostat

Pain is not simply a signal your nerves generate — it is a sensation your brain calibrates continuously, amplifying or dampening incoming nociceptive input based on the availability of pain-modulating neuropeptides. The EIPR1 gene¹¹ EIPR1 gene
EARP complex and GARP complex interacting protein 1; also known by its original name TSSC1 (tumor-suppressing subtransferable candidate 1); located on chromosome 2p25.3 encodes a WD40-domain protein that sits at an unexpected point of control in this system: the sorting of neuropeptides into the dense-core vesicles that neurons use for regulated, stimulus-triggered release.

The Mechanism

EIPR1 acts as a molecular bridge between two endosomal trafficking complexes — EARP (endosome-associated recycling protein)²² EARP (endosome-associated recycling protein)
Retrieves membrane proteins from endosomes back to the plasma membrane and GARP (Golgi-associated retrograde protein), which returns cargo from endosomes to the trans-Golgi network. Together these complexes manage the endosomal sorting compartment, a staging area through which neuropeptide precursors pass on their way into mature dense-core vesicles (DCVs).

Dense-core vesicles³³ Dense-core vesicles
Large secretory organelles distinct from conventional synaptic vesicles; they package and release neuropeptides, biogenic amines, and peptide hormones including substance P, CGRP, enkephalins, and brain-derived neurotrophic factor are the primary vehicles for neuropeptide secretion throughout the nervous system. When EIPR1 function is impaired, cargo fails to sort correctly into maturing DCVs — it accumulates in the perinuclear region rather than being packaged and shipped to axonal terminals. Loss of EIPR1 in insulin-secreting cells reduces regulated secretion⁴⁴ Loss of EIPR1 in insulin-secreting cells reduces regulated secretion
Topalidou et al. 2020 and disrupts EARP localization on endosomal membranes.

In the brain, EIPR1 is expressed broadly, with highest levels in the basal ganglia, cerebral cortex, amygdala, and hypothalamus — regions central to both pain processing and descending pain modulation. The intronic rs58194899 variant likely modulates EIPR1 expression or splicing efficiency in a tissue-specific manner rather than altering the protein sequence directly. The A allele, which reduces pain sensitivity, may increase EIPR1 activity or expression in relevant neural circuits, improving neuropeptide packaging and thereby enhancing endogenous pain suppression.

The Evidence

Fontanillas et al. 2022⁵⁵ Fontanillas et al. 2022
23andMe GWAS; 25,321 participants scored on the Pain Sensitivity Questionnaire; cold pressor test arm (n=6,853) did not replicate this signal performed the largest genetic analysis of self-reported pain sensitivity to date. The rs58194899 A allele reached genome-wide significance (OR = 0.950, 95% CI 0.933–0.967, p = 1.9 × 10⁻⁸, MAF = 0.47) for lower PSQ scores, meaning each copy of the A allele is associated with approximately 5% lower odds of rating yourself as highly pain sensitive. The haplotype block spans 54 variants entirely within EIPR1's boundaries, implicating the gene specifically.

Importantly, the signal was not replicated in the cold pressor test (CPT) arm (p = 0.58), suggesting this variant influences subjective pain perception and central sensitization rather than peripheral nociceptive thresholds measured by acute cold pain tolerance.

Pathway enrichment analysis in the same study showed that PSQ-associated genes are overrepresented in neuronal development and glutamatergic synapse signaling pathways — consistent with a mechanism involving neuropeptide modulation of synaptic plasticity and central sensitization.

Recent clinical genetics work Ghosh et al. 2025⁶⁶ Ghosh et al. 2025
Eight individuals from six families with homozygous pathogenic EIPR1 variants; global developmental delays, corpus callosum underdevelopment, cerebellar atrophy confirms that severe EIPR1 loss of function produces a neurodevelopmental disorder with hallmark endolysosomal and dense-core vesicle defects — providing strong biological plausibility that common regulatory variation at this locus modifies neural function along a continuum.

The evidence level is rated emerging: the GWAS association is genome-wide significant and biologically coherent, but there is currently one discovery study without independent replication, and the functional mechanism (how exactly the intronic variant modulates EIPR1 in pain-relevant circuits) has not been characterized.

Practical Actions

This variant does not predict response to a specific drug class the way CYP2D6 or OPRM1 variants do. Instead, it shifts the baseline at which you perceive and report pain — a contextual factor that informs analgesic strategy and pain assessment.

For the GG genotype (higher pain sensitivity): standard pain scales may underestimate the need for analgesic coverage, particularly for perioperative and chronic pain. A proactive, multimodal approach — combining pharmacological and non-pharmacological pain management — is more likely to achieve adequate control than relying on reactive dose escalation.

For the AA genotype (lower pain sensitivity): standard doses of analgesics may provide sufficient effect, but there is also a risk of under-recognition of pain (your own and by providers) in conditions where pain is a key diagnostic signal.

Interactions

The pain sensitivity pathway involves multiple genetic modulators. OPRM1 rs1799971⁷⁷ OPRM1 rs1799971
Mu-opioid receptor A118G variant — G allele reduces receptor expression and opioid efficacy independently affects opioid analgesic response. Individuals carrying both high-sensitivity EIPR1 GG and OPRM1 G alleles face a double challenge: heightened pain experience combined with reduced opioid effectiveness. The COMT rs4680⁸⁸ COMT rs4680
Catechol-O-methyltransferase Val158Met — Met/Met associated with lower dopamine catabolism and higher pain sensitivity is another convergent pain sensitivity modifier worth considering when interpreting EIPR1 GG results. These interactions are not yet characterized in combined analyses and cannot support specific compound action recommendations, but awareness of co-occurring risk genotypes is clinically useful.